prasugrel / clopidogrel — Competitive Intelligence Brief

prasugrel / clopidogrel (prasugrel / clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (thienopyridine). Area: Cardiovascular.

marketed P2Y12 receptor antagonist (thienopyridine) P2Y12 receptor Cardiovascular Small molecule

Target snapshot

prasugrel / clopidogrel (prasugrel / clopidogrel) — Assistance Publique - Hôpitaux de Paris. Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
prasugrel / clopidogrel TARGET	prasugrel / clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
Beta blocker, aspirin, clopidogrel	Beta blocker, aspirin, clopidogrel	Spanish Society of Cardiology	marketed	Combination antithrombotic and antihypertensive therapy	Beta-adrenergic receptors; COX-1; P2Y12 receptor
Switch ticagrelor to clopidogrel	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (thienopyridine) class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Azienda Policlinico Umberto I · 1 drug in this class
3. Deutsches Herzzentrum Muenchen · 1 drug in this class
4. Elliot Israel, MD · 1 drug in this class
5. Research Maatschap Cardiologen Rotterdam Zuid · 1 drug in this class
6. Sanofi · 1 drug in this class